Nouscom
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • Meetings
    • Press Releases
    • Publications
  • Contact
Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • Meetings
    • Press Releases
    • Publications
  • Contact

Archives

Monthly Archive for: "Dicembre, 2020"
Home » Archivi per Dicembre 2020
0

Nouscom appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer

BASEL, Switzerland – 11th December 2020: Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized genetic cancer vaccines, today announces that it has appointed [...]

READ MORE
0

Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment

Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an [...]

READ MORE
0

New viral vectors for infectious diseases and cancer

ABSTRACT – Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and finally eradicate smallpox, the concept of using a virus to fight another virus has evolved [...]

READ MORE
Contact
  • NOUSCOM
  • info@nouscom.com
  • nouscom.com
Our Privacy

Privacy Policy & Cookie Low

Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

© Copyright 2018 | Made with by
error: Content is protected !!!
Utilizziamo i cookie per essere sicuri che tu possa avere la migliore esperienza sul nostro sito. Se continui ad utilizzare questo sito noi assumiamo che tu ne sia felice.Ok